Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Teva Pharma Industries Ltd ADR (NYSE: TEVA) is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a line ...

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

FREE TO READ] Critics say fragmented ownership, weak culture and a fixation on financial results have harmed innovation ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Experts are calling on the government to implement strategies that will better predict future Ozempic shortages.

Alphabet investors will be looking for updates on spending, search competition, cloud performance and regulatory news when the Google parent reports earnings Tuesday night. Alphabet is scheduled to ...

2-Year U.S. Treasury Note Continuous Contract $102.746 0.020 0.02% 5-Year U.S. Treasury Note Continuous Contract $106.086 0.016 0.01% 10-Year U.S. Treasury Note Continuous Contract $108.391 0.016 ...